Modified Tumor-Derived Exosomes for Colorectal Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Colorectal cancer (CRC) tumors are often nonimmunogenic and unresponsive to current immune checkpoint inhibitor-based therapies due to immunosuppressive factors present in tumor-derived extracellular vesicles (EVs).
Innovation Solution
Modified tumor-derived EVs isolated from tumor cells with reduced or lacking expression of immune suppressive factors, such as miR-424, are used to enhance immune response against tumors. These EVs can be used as a vaccine or in combination with checkpoint inhibitor therapies to improve cancer treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tumor-derived EVs are used to stimulate tumor-specific immunity, then immune response is enhanced, but immunosuppressive factors (PD-L1, miRNAs) in the EVs compromise the immune stimulation effect
Solution Approach 1:
The patent extracts and removes immunosuppressive factors (PD-L1, miRNAs) from tumor-derived EVs through selective isolation methods, producing purified EVs that contain tumor antigens but lack harmful immunosuppressive components. This extraction process enables the EVs to effectively stimulate tumor-specific immunity without being compromised by their own immunosuppressive factors.
Solution Approach 2:
The patent modifies the composition and properties of tumor-derived EVs by changing key parameters such as purity, concentration of tumor antigens, and absence of immunosuppressive factors. Through controlled isolation and characterization, the EVs are transformed from immunosuppressive-containing forms to purified forms that enhance immune response efficacy.
2Reliability
If 85% of CRC tumors are nonimmunogenic and lack tumor-infiltrating T cells, then current immune checkpoint inhibitor-based therapies become unresponsive, but the invention aims to increase immune response to these tumors
Solution Approach 1:
The patent employs preliminary action by using tumor-derived EVs as a vaccine to pre-stimulate the immune system before the actual tumor treatment. The EVs contain tumor antigens that can prime T cells and enhance immune surveillance, making the immune system more responsive to subsequent immune checkpoint inhibitor therapy, thereby overcoming the nonimmunogenic state of CRC tumors.
3Reliability
If immunosuppressive components are present in tumor-derived EVs, then tumor immunity stimulating effects are compromised, but removing these components requires complex isolation and characterization processes
Solution Approach 1:
The patent applies segmentation by dividing the complex EV isolation process into distinct, manageable steps: EV extraction, purification, characterization, and functional validation. Each step focuses on specific aspects such as removing immunosuppressive factors, verifying purity, and confirming biological activity. This segmented approach makes the complex process of producing immunosuppressive-free EVs more systematic and reproducible.
Data Source
Figure 1A~1D
Figure 2A~2G
Figure 3A~3G
AI summary
The present invention provides tumor-derived extracellular vesicles (EVs) lacking an immune suppressive factor, for example, miR-424, methods of making and methods of use for treating cancer. Further the present invention provide vaccine compositions comprising modified tumor-derived EVs for use in treating secondary tumors.